The biochip for the treatment of diabetes



research in the field of diabetes are not standing still. This is largely due to the difficulties that exist in its diagnosis and treatment today and desire to fix them, to make life easier for the huge number of diabetic patients.

So, the Swiss concern pharmacology "Roshe" has developed a unique new product - the biochip. This compact invention, which today, unfortunately, only available to the American consumer market, providing invaluable assistance in the appointment of patients with diabetes appropriate medication.

it's No secret that diabetes is a disease, treatment non. It can only control and reduce the symptoms, correct selection of drugs. Unfortunately, the situation with this disease had been formed so that the drugs mostly prescribed by doctors blindly. If one of the prescribed medications did not answer, just appointed the next and so on until a positive effect. Because of this, more than 2 million diabetic patients annually were forced to treat their underlying disease, but the consequences of incorrectly assigned pills or injections. Frequent were cases when due to intolerance of a certain drug in a patient was approaching death. Annually only in the United States of America and for this reason I died about a hundred thousand people.

a biochip for the treatment of diabetes mellitusthe Technology for the biochip was invented and developed by the staff of the American company "Affymetrix". To obtain objective information, the biochip uses taken from the patient a drop of blood or saliva sample taken in the oral cavity.

the Latter, incidentally, is an important advantage of this invention because it does not require special laboratory conditions, such as a blood test.

the Biochip works on the principle of determining the possible mutations of those genes that are involved in the absorption of 25% of the drugs that are offered to diabetic patients with a prescription, including antidepressants and drugs to reduce pressure.

Experts suggest that widespread use of these biochips is able to reduce the deaths of patients from incorrectly chosen medication approximately 20 percent, while total mortality is quite high.